Dr. Peter A. Kiener is a venture partner within the life sciences team at ICG, a global leader in alternative asset management, and also serves as a biotech/biopharma consultant. Prior to this, he served as Chief Executive Officer of Cereius Inc., a developer of radiodiagnostics and radiotherapeutics for cancer, as CSO and Head of Research and Development at Sucampo Pharma Inc, a fully integrated biopharma company, and CSO of Ambryx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates.

Earlier in his career, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company.  He also held leadership roles of increasing responsibility over an eight year span at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research.  Dr. Kiener previously worked on biologics for Bristol-Myers Squibb. He began his career at the University of North Texas/Texas College of Osteopathic Medicine, where he was an Assistant Professor, and the University of Massachusetts at Amherst, where he was a Research Associate.  Dr. Kiener has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation. Dr. Kiener currently serves as Chairman of the Board of Managers of Resolve LLC, and is a member of the Board of Directors of Cue Pharma LLC, Pieris, and Lava Therapeutics.

He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. Dr. Kiener earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.